Syndax Q2 2022 Earnings Report
Key Takeaways
Syndax Pharmaceuticals reported its financial results for the second quarter ended June 30, 2022. Key highlights include advancements in the clinical development of revumenib and axatilimab, with topline data expected in the first half of 2023.
On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23.
Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q22.
Pivotal Phase 2 portion of AUGMENT-101 is ongoing, with completion of enrollment expected by year-end.
Company plans to initiate a Phase 2b trial of axatilimab in patients with IPF in the fourth quarter of 2022.
Syndax
Syndax
Forward Guidance
The Company expects research and development expenses to be $25 to $30 million, and total operating expenses to be $35 to $40 million for the third quarter of 2022. For the full year of 2022, the Company continues to expect research and development expenses to be $130 to $140 million and total operating expenses to be $160 to $170 million.